Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease
Background: Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized controlled trials.Aim: To perform a mixed comparison...
Main Authors: | Guozhi Wu, Yuan Yang, Min Liu, Yuping Wang, Qinghong Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.655865/full |
Similar Items
-
Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01) -
Biosimilar infliximab versus originator in Crohn’s
disease anti-TNF-α naïve and non-naïve patients
by: Magdalena Kaniewska, et al.
Published: (2020-11-01) -
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis
by: Josef S. Smolen, et al.
Published: (2020-08-01) -
Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review
by: Stefan Siedlikowski, et al.
Published: (2019-11-01) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012-03-01)